Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy
- 1 March 1992
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 10 (1) , 31-34
- https://doi.org/10.1007/bf01275477
Abstract
Fifteen patients with advanced head and neck cancer not curable with radiation or surgery were entered into a phase II study of 10-EdAM. None of the patients had received prior chemotherapy. 10-EdAM was administered intravenously at a dose of 80 mg/m2 each week. Four patients were not eligible for evaluation. Two died before completing four cycles of chemotherapy, one refused further treatment and one developed hepatic toxicity resulting in withdrawal. Of the remaining patients, three had a partial response. The major toxicities were leukopenia and mucositis.Keywords
This publication has 4 references indexed in Scilit:
- PHASE-1 TRIAL AND CLINICAL PHARMACOLOGICAL EVALUATION OF 10-ETHYL-10-DEAZAAMINOPTERIN IN ADULT PATIENTS WITH ADVANCED CANCER1988
- Trimetrexate as a single agent in patients with advanced head and neck cancer.1988
- Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.Journal of Clinical Oncology, 1988
- NEW FOLATE ANALOGS OF THE 10-DEAZA-AMINOPTERIN SERIES - FURTHER EVIDENCE FOR MARKEDLY INCREASED ANTITUMOR EFFICACY COMPARED WITH METHOTREXATE IN ASCITIC AND SOLID MURINE TUMOR-MODELS1984